Shuttle Pharmaceuticals Holdings, Inc.

SHPH Nasdaq CIK: 0001757499

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation DE
Business Address 401 PROFESSIONAL DRIVE, GAITHERSBURG, MD, 20879
Mailing Address 401 PROFESSIONAL DRIVE, GAITHERSBURG, MD, 20879
Phone (240) 403-4212
Fiscal Year End 1231
EIN 000000000

Financial Overview

FY2025

Recent SEC Filings

Form Type Date Filed Document
10-K Annual financial report March 31, 2026 View on SEC
8-K Current report of material events March 10, 2026 View on SEC
8-K Current report of material events February 17, 2026 View on SEC
S-1 IPO registration statement February 11, 2026 View on SEC
S-1/A IPO registration amendment February 11, 2026 View on SEC
8-K Current report of material events February 2, 2026 View on SEC
8-K Current report of material events January 12, 2026 View on SEC
3 Initial insider ownership report January 12, 2026 View on SEC
8-K Current report of material events December 29, 2025 View on SEC
S-1/A IPO registration amendment December 11, 2025 View on SEC

Annual Reports

10-K March 31, 2026
  • Strategic pivot from traditional drug development to an AI-driven pharmaceutical research platform.
  • Acquisition of Molecule.ai for $10 million in stock to anchor new AI technology business model.
View Analysis

Material Events

8-K Acquisition December 29, 2025
High Impact
  • Shuttle Pharmaceuticals issued 320,496 new common shares to 1542770 BC Ltd. as an accelerated payment.
  • This share issuance covers a portion of the 'First Installment Payment' for an ongoing asset acquisition.
View Analysis

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.